A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy and safety of bevacizumab + fotemustine in patients
with stage IV melanoma, previously untreated with chemo- or immunotherapy for metastatic
disease. Patients will receive Avastin (15mg/kg intravenously[IV]) on Day 1 of every 3 week
cycle, in combination with fotemustine (100mg/m² IV) on Days 1, 8 and 15, followed by 4 weeks
rest, followed by 100mg/m² IV every 3 weeks for 4-6 cycles. The anticipated time on study
treatment is until disease progression, and the target sample size is <100 individuals.